Why Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA And Collaboration Shift [Yahoo! Finance]
Protagonist Therapeutics, Inc. (PTGX)
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.protagonist-inc.com
Company Research
Source: Yahoo! Finance
US$44.38 million for the quarter and US$130.15 million for the year, alongside weaker per-share performance. At the same time, the company advanced its pipeline by submitting a New Drug Application for rusfertide, outlining plans to alter its collaboration economics with Takeda, and signaling an upcoming U.S. regulatory decision for ICOTYDE in 2026. With these earnings setbacks alongside the rusfertide NDA submission, we'll examine how this combination reshapes Protagonist Therapeutics' investment narrative. The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. What Is Protagonist Therapeutics' Investment Narrative? For Protagonist Therapeutics, the core belief you'd need as a shareholder is that today's losses are the cost of building a commercial franchise around rusfertide and ICOTYDE. The latest results underscored that trade-off: a swing to a US$130.15 million annual net l
Show less
Read more
Impact Snapshot
Event Time:
PTGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTGX alerts
High impacting Protagonist Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTGX
News
- Protagonist Therapeutics (PTGX) had its price target raised by The Goldman Sachs Group, Inc. from $65.00 to $95.00. They now have a "neutral" rating on the stock.MarketBeat
- Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera [Yahoo! Finance]Yahoo! Finance
- Protagonist Therapeutics (PTGX) had its price target raised by TD Cowen from $90.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
- Protagonist Therapeutics (PTGX) had its price target raised by Barclays PLC from $108.00 to $113.00. They now have an "overweight" rating on the stock.MarketBeat
- Protagonist Therapeutics (PTGX) had its price target raised by Citizens Jmp from $102.00 to $112.00. They now have a "market outperform" rating on the stock.MarketBeat
PTGX
Earnings
- 2/25/26 - Miss
PTGX
Sec Filings
- 2/25/26 - Form S-8
- 2/25/26 - Form 10-K
- 2/25/26 - Form 8-K
- PTGX's page on the SEC website